CUPR (Cuprina Holdings (Cayman) Limited) shareholders approved increasing the company’s authorized share capital from US$100,000 divided into 12,500,000 ordinary shares to US$10,000,000 divided into 1,250,000,000 ordinary shares, with 625,000,000 shares each designated Class A and Class B.
At the October 15, 2026 extraordinary general meeting, shareholders also approved amended articles that lower the threshold for written ordinary resolutions to a simple majority of the voting rights entitled to vote on the resolution. They approved directing the meeting chair to adjourn if necessary for further proxy solicitation and voting if the tabulated votes were insufficient for the first two proposals. All three proposals passed. As of September 8, 2026, 920,644 Class A and 1,760,625 Class B shares were issued and outstanding; each Class A share carried one vote and each Class B share carried 100 votes.
Cuprina Holdings (Cayman) Limited (CUPR), through its wholly owned subsidiary, entered into conditional agreements to acquire all shares in East Coast Podiatry Centre and Orchard Clinic Management for approximately S$4.0 million (approximately US$3.1 million). Consideration comprises S$3.0 million in cash and S$1.0 million in Class A ordinary shares: 60,334 shares under SPA I and 241,337 under SPA II, subject to lock-ups. The targets operate five podiatry clinics and two women’s health and wellness clinics in Singapore.
Completion is conditional on shareholder approval to increase Cuprina’s authorized share capital at an extraordinary general meeting on October 15, 2026; the stated timetable is after that meeting and on or before November 1, 2026. For the year ended December 31, 2025, the targets reported combined unaudited revenue of S$9.1 million and normalized EBITDA of S$1.2 million, based on management accounts and subject to possible adjustment upon audit. Upon completion, the targets are to become wholly owned subsidiaries, and the consideration shares would represent approximately 3.79% of enlarged issued Class A ordinary shares.
Cuprina Holdings (Cayman) Limited issued and sold 648,373 additional Class A ordinary shares on September 29, 2026, at $1.15 per share, following full exercise of the underwriters’ 45-day over-allotment option. The sale generated approximately $745,629 in additional gross proceeds. The company reported approximately $5,716,491 in aggregate gross proceeds from the public offering, including the over-allotment shares, before underwriting discounts, commissions and estimated offering expenses.
Cuprina also issued R. F. Lafferty, as representative of the underwriters, warrants to purchase up to 25,935 shares at an initial exercise price of $1.265 per share. The warrants are exercisable during the four and one-half year period commencing six months from the commencement of sales of the public offering, and include a one-time demand registration right and unlimited piggyback rights expiring five years from commencement of sales. Net proceeds are intended for new-business expansion, research and development, product offerings, new markets, brand awareness, equipment and infrastructure, working capital and general corporate purposes.
Cuprina Holdings (Cayman) Limited (CUPR) has called an extraordinary general meeting of shareholders for October 15, 2026 to vote on a substantial expansion of its authorized share capital and related governance changes. The record date for voting eligibility is September 8, 2026.
Proposal 1 seeks to increase authorized share capital from US$100,000 divided into 12,500,000 Ordinary Shares (6,250,000 Class A and 6,250,000 Class B, par US$0.008) to US$10,000,000 divided into 1,250,000,000 Ordinary Shares (625,000,000 Class A and 625,000,000 Class B). Proposal 2 would adopt a Third Amended and Restated Memorandum and Articles of Association, including reflecting the increased authorized capital (if approved) and lowering the threshold for written ordinary resolutions to a simple majority of voting rights. Proposal 3 would allow the chair to adjourn the meeting to solicit additional proxies if there are insufficient votes to pass Proposals 1 and 2. The board unanimously recommends voting in favor of all proposals.
Cuprina Holdings (Cayman) Limited (CUPR) completed a public offering of 4,322,489 Class A ordinary shares at $1.15 per share, generating approximately $4.97 million in gross proceeds, before underwriting discounts and offering expenses. A Registration Statement on Form F-1 for this offering was declared effective on September 15, 2026.
The company granted the underwriter a 45‑day option to purchase up to an additional 648,373 Class A ordinary shares at the same price, which would increase gross proceeds to about $5.72 million if fully exercised. Cuprina plans to use the net proceeds for expansion into new businesses, R&D, market growth, brand building, equipment and infrastructure, and working capital and general corporate purposes.
As compensation to the underwriters, Cuprina issued Representative’s Warrants to purchase up to 172,900 Class A ordinary shares at an exercise price of $1.265 per share, equal to 110% of the offering price. These warrants are exercisable starting six months after the commencement of sales, for a four‑and‑one‑half‑year period, and include registration rights and customary anti‑dilution provisions.
Cuprina Holdings (Cayman) Limited (CUPR) is conducting a primary public offering of 4,322,489 Class A Ordinary Shares at $1.15 per share, a discount to the $2.93 Nasdaq closing price on September 15, 2026, underwritten on a firm commitment basis with a 45‑day over‑allotment option for 648,373 additional shares.
Before the deal, Cuprina has 920,644 Class A and 1,760,625 Class B shares outstanding; after the offering it expects 5,243,133 Class A and 1,760,625 Class B shares (excluding the option), with Class B carrying 100 votes per share and remaining convertible 1‑for‑1 into Class A, so the company will continue as a controlled company under Nasdaq rules.
Net proceeds are estimated at about $4.33 million (or $5.02 million with full option exercise), to be used for supply chain expansion, marketing and promotion, and working capital. Cuprina is a Cayman holding company with operations conducted through subsidiaries in Singapore and other jurisdictions; investors in the listed Class A shares may never directly hold equity in those operating subsidiaries.
Cuprina Holdings (Cayman) Limited (CUPR) plans a firm-commitment primary offering of 4,322,489 Class A Ordinary Shares, with an estimated public offering price range of $1.00–$1.50 per share, plus an over-allotment option for 648,373 additional shares. Representative’s Warrants equal to 4.0% of shares sold will be issued at an exercise price of 110% of the final offering price.
After the offering, Cuprina expects 5,243,133 Class A and 1,760,625 Class B shares outstanding (excluding the over-allotment). The company is a Cayman holding company whose operating subsidiaries run a Singapore-based biomedical and biotechnology business focused on chronic wound care (including MEDIFLY maggot therapy dressings) and cosmeceuticals across Singapore, Hong Kong, Saudi Arabia, Malaysia and mainland China.
Cuprina is an emerging growth company and foreign private issuer, and will remain a controlled company because Cuprina Holding Pte. Ltd. will continue to hold over 50% of voting power via 100-vote Class B shares. The business is early-stage with small revenues (about S$49,894 in 2025) and significant net losses (about S$4,673,447 in 2025), and recorded net operating cash outflows in 2024 and 2025. Net proceeds of approximately $3.74 million (or $4.33 million with full over-allotment, assuming $1.00 per share) are earmarked for supply chain expansion, marketing and working capital.
Cuprina Holdings (Cayman) LTD has a new significant shareholder disclosure from Jane Street entities regarding its Class A Ordinary Shares, par value US$0.008 per share. Jane Street Group, LLC reports beneficial ownership of 46,466 shares, representing 5.1% of this class.
All 46,466 shares are reported with shared voting and shared dispositive power and no sole power. Within the group, Jane Street Capital, LLC reports 30,589 shares (3.3% of the class), and Jane Street Global Trading, LLC reports 15,877 shares (1.7% of the class), both on a shared-power basis. The filing identifies Jane Street Capital, LLC and Jane Street Global Trading, LLC as subsidiaries connected to the reported holdings.
Cuprina Holdings (Cayman) Limited is conducting a proposed public offering of Class A Ordinary Shares listed on Nasdaq under the symbol CUPR. The prospectus states there will be an issuance of Class A Ordinary Shares and an underwriter option to purchase additional shares.
The company reported revenue of S$49,894 (US$38,789) and a net loss of S$4,673,447 (US$3,633,248) for the year ended December 31, 2025. Immediately prior to the offering the company had 920,625 Class A and 1,760,625 Class B ordinary shares outstanding. Cuprina received FDA 510(k) clearance for its MEDIFLY products on June 12, 2026 (510(k) No. BK251252) and the Saudi FDA classified MEDIFLY as a Medical Device–Drug combination product in January 2026.